Back to Search
Start Over
The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial.
- Source :
-
Diabetologia [Diabetologia] 2024 Dec; Vol. 67 (12), pp. 2637-2649. Date of Electronic Publication: 2024 Sep 14. - Publication Year :
- 2024
-
Abstract
- Aims/hypothesis: Dipeptidyl peptidase-4 (DPP-4) inhibition has beneficial effects on various metabolic indicators in diabetes. Stromal cell-derived factor-1 (SDF-1) is expressed in diverse organs including the kidneys and is cleaved and inactivated by DPP-4 enzyme. The aim of this study was to conduct a randomised controlled trial to assess the effect of sitagliptin on diabetic nephropathy when used as an add-on therapy to the advanced hybrid closed-loop (AHCL) system in adolescents with type 1 diabetes and nephropathy.<br />Methods: This open-label, parallel-group, randomised controlled trial took place at the Pediatric Diabetes Clinic, Ain Shams University, Egypt. Forty-six adolescents aged 14.13 ± 2.43 years on the MiniMed 780G system for at least 6 months before study, with HbA <subscript>1c</subscript> ≤69 mmol/mol (8.5%) and diabetic nephropathy in the form of microalbuminuria, were randomly assigned to two groups (n=23 for each) based on a computer-generated randomisation sequence. The intervention group received oral sitagliptin 50 mg for 3 months. The other group used AHCL only and served as a control group. The primary outcome measure was the change in urinary albumin/creatinine ratio (UACR) after 3 months of administration of sitagliptin. The key secondary outcome measure was the change from baseline in SDF-1 levels after treatment.<br />Results: Data for all participants were analysed. No significant difference was found between the groups as regards baseline clinical and laboratory characteristics as well as AHCL system settings (p>0.05). Serum SDF-1 levels were higher in all individuals with type 1 diabetes vs healthy control individuals (p<0.001). After 3 months, sitagliptin resulted in a significant decrease of SDF-1 levels from 3.58 ± 0.73 to 1.99 ± 0.76 ng/ml (p<0.001), together with improvement of UACR from 7.27 ± 2.41 to 1.32 ± 0.31 mg/mmol (p<0.001). In addition, sitagliptin reduced postprandial glucose, sensor glucose, coefficient of variation and total daily dose of insulin, while time in range 3.9-10.0 mmol/l (70-180 mg/dl) and insulin-to-carbohydrate ratio were significantly increased. Sitagliptin was safe and well-tolerated without severe hypoglycaemia or diabetic ketoacidosis.<br />Conclusions/interpretation: Sitagliptin as an add-on therapy to AHCL had a reno-protective effect for individuals with type 1 diabetes and diabetic nephropathy, in addition to the improvement of time in range while reducing glycaemic variability and without compromising safety.<br />Funding: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.<br />Trial Registration: ClinicalTrials.gov NCT06115460.<br />Competing Interests: Declarations. Acknowledgements: The authors thank all the participants and their families for their collaboration during the study. Data availability: The data are available on reasonable request from the authors. Funding: Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. Authors’ relationships and activities: The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. Contribution statement: All authors (NSE, EAI, MHE-H, MZI, AAE) contributed substantially to the study design, analysis or interpretation of data; critically reviewed, drafted or edited the manuscript; and approved the final work for submission. NSE is responsible for the integrity of the work as a whole.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Adolescent
Male
Female
Child
Glycated Hemoglobin metabolism
Hypoglycemic Agents therapeutic use
Hypoglycemic Agents administration & dosage
Chemokine CXCL12 blood
Chemokine CXCL12 metabolism
Insulin Infusion Systems
Insulin
Sitagliptin Phosphate therapeutic use
Sitagliptin Phosphate administration & dosage
Diabetes Mellitus, Type 1 drug therapy
Diabetes Mellitus, Type 1 complications
Diabetic Nephropathies drug therapy
Dipeptidyl-Peptidase IV Inhibitors therapeutic use
Dipeptidyl-Peptidase IV Inhibitors administration & dosage
Glycemic Control methods
Blood Glucose drug effects
Blood Glucose metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1432-0428
- Volume :
- 67
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Diabetologia
- Publication Type :
- Academic Journal
- Accession number :
- 39271520
- Full Text :
- https://doi.org/10.1007/s00125-024-06265-7